ReviewAnnals of joint2022
Narrative review of the epidemiology, economic burden, and societal impact of metastatic bone disease.
Review in Annals of joint, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- BoneCoT: multicentre validation of a whole-body skeleton foundation model for bone metastases guided by clinician-derived chain of thought.Nature biomedical engineering · 2026Article
- Trends and Disparities in Secondary Malignant Neoplasms of the Bone in the United States: The WONDER Study.Cancers · 2026Article
- Cost-effectiveness analysis of a bone metastasis cancer board for skeletal-related events of breast cancer.Japanese journal of clinical oncology · 2026Article
- SHIELD: An AI Framework for Skeletal Health Intelligence and Early Lesion Detection to Improve Orthopedic Referrals.Journal of medical systems · 2026Article
- Post-operative survival and use of systemic therapy in metastatic long-bone disease: 12 years of institutional experience.Journal of bone oncology · 2026Article
- The Neuro-Bone Axis in Metastatic Progression: Innervation, Neuro-Immune-Osteoclast Crosstalk, and Therapeutic Opportunities.Biology · 2026Review
- Artificial Intelligence and Machine Learning in Bone Metastasis Management: A Narrative Review.Current oncology (Toronto, Ont.) · 2026Review
- The Importance of Closed Reduction and Internal Fixation done with Intramedullary Implants in Pathological Fractures - A Case Series.Journal of orthopaedic case reports · 2026Article
- Cancer and total hip arthroplasty: a narrative review of clinical intersections, challenges and outcomes.Orthopedic reviews · 2026Article
- Discrepancy between X-ray and CT assessment in the Mirels score for long bone metastasis.BMC musculoskeletal disorders · 2025Article
- Article
- Epidemiology and Future Burden of Vertebral Fractures: Insights from the Global Burden of Disease 1990-2021.Healthcare (Basel, Switzerland) · 2025Article
- Sending the Signal to Bone: How Tumor-Derived EVs Orchestrate Pre-Metastatic Niche Formation and Skeletal Colonization.Biomedicines · 2025Review
- Artificial Intelligence in bone Metastases: A systematic review in guideline adherence of 92 studies.Journal of bone oncology · 2025Review
- Hospital-related healthcare expenditure of impending versus completed pathological femur fractures: a propensity score matched study of 265 patients.Acta orthopaedica · 2025Article
- Review of Bone Metastasis in Gynecologic Malignancies: Evaluation and Treatment.Current treatment options in oncology · 2025Review
- Review
- A comprehensive evaluation of intramedullary devices in the management of femoral metastasis: 30-day outcomes.Proceedings (Baylor University. Medical Center) · 2025Article
- Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone.Cancer research communications · 2024Article
- Current Advances in the Use of Tissue Engineering for Cancer Metastasis Therapeutics.Polymers · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the prevalence of cancer continues to rise in the United States due to a combination of both early detection and increased life expectancy, the number of clinically symptomatic skeletal metastases will continue to grow. Healthcare expenditures on cancer treatment have steadily increased each decade to our estimated level of approximately $200 billion in 2020. Metastatic bone disease is a significant driver of this cost, accounting for nearly one-fifth of the total cost of oncologic treatment. Understanding the impact of metastatic bone disease can help to identify the gaps between diagnosis and initiation of treatment in an effort to decrease the socioeconomic and psychosocial implications of the disease. In this paper, we review the epidemiology and economic burden of metastatic bone disease in addition to other sequelae that affect patients, including financial hardship, caregiver burden, diminished quality of life and psychological impact. Upon literature review of multiple studies investigating these factors, we found that advanced metastatic bone disease had overall poor outcomes with regards to the socioeconomic and psychosocial effects on not only patients and their families, but also society at large. These consequences may be improved by early referral to orthopedic specialists and establishment of a multi-disciplinary team.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.